News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
843,249 Results
Type
Article (86299)
Company Profile (655)
Press Release (756295)
Section
Business (232592)
Career Advice (4125)
Deals (39710)
Drug Delivery (128)
Drug Development (90940)
Employer Resources (198)
FDA (18071)
Job Trends (17317)
News (396271)
Policy (39704)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (7)
2025 BioForest Digital (7)
2025 Lone Star Bio Digital (9)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2993)
Academic (2)
Accelerated approval (5)
Adcomms (29)
Allergies (88)
Alliances (56765)
ALS (93)
Alzheimer's disease (1479)
Antibody-drug conjugate (ADC) (141)
Approvals (18039)
Artificial intelligence (285)
Autoimmune disease (22)
Automation (14)
Bankruptcy (404)
Best Places to Work (12633)
BIOSECURE Act (21)
Biosimilars (115)
Biotechnology (450)
Bladder cancer (65)
Brain cancer (30)
Breast cancer (275)
Cancer (2176)
Cardiovascular disease (189)
Career advice (3529)
Career pathing (33)
CAR-T (161)
Cell therapy (453)
Cervical cancer (21)
Clinical research (73118)
Collaboration (842)
Compensation (482)
Complete response letters (30)
COVID-19 (2858)
CRISPR (43)
C-suite (232)
Cystic fibrosis (105)
Data (2039)
Decentralized trials (2)
Denatured (43)
Depression (50)
Diabetes (275)
Diagnostics (6884)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (127)
Drug pricing (122)
Drug shortages (33)
Duchenne muscular dystrophy (93)
Earnings (96222)
Editorial (39)
Employer branding (25)
Employer resources (167)
Events (129261)
Executive appointments (692)
FDA (19262)
Featured Employer (64)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (752)
Gene editing (111)
Generative AI (28)
Gene therapy (325)
GLP-1 (825)
Government (5119)
Grass and pollen (5)
Guidances (49)
Healthcare (20877)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (129)
Indications (27)
Infectious disease (3007)
Inflammatory bowel disease (148)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (91)
Interviews (812)
IPO (17794)
IRA (51)
Job creations (5184)
Job search strategy (2861)
Kidney cancer (10)
Labor market (38)
Layoffs (540)
Leadership (20)
Legal (10102)
Liver cancer (76)
Lung cancer (317)
Lymphoma (139)
Machine learning (4)
Management (65)
Manufacturing (308)
MASH (68)
Medical device (14576)
Medtech (14581)
Mergers & acquisitions (22392)
Metabolic disorders (730)
Multiple sclerosis (79)
NASH (23)
Neurodegenerative disease (103)
Neuropsychiatric disorders (31)
Neuroscience (2024)
NextGen: Class of 2025 (7667)
Non-profit (5077)
Northern California (2520)
Now hiring (38)
Obesity (397)
Opinion (270)
Ovarian cancer (75)
Pain (90)
Pancreatic cancer (79)
Parkinson's disease (148)
Partnered (22)
Patents (221)
Patient recruitment (101)
Peanut (51)
People (65077)
Pharmaceutical (134)
Pharmacy benefit managers (21)
Phase I (22556)
Phase II (31746)
Phase III (23937)
Pipeline (1107)
Podcasts (122)
Policy (140)
Postmarket research (3552)
Preclinical (10129)
Press Release (72)
Prostate cancer (99)
Psychedelics (38)
Radiopharmaceuticals (267)
Rare diseases (405)
Real estate (7386)
Recruiting (75)
Regulatory (26658)
Reports (57)
Research institute (2654)
Resumes & cover letters (649)
Rett syndrome (4)
RNA editing (4)
RSV (47)
Schizophrenia (76)
Series A (133)
Series B (84)
Service/supplier (27)
Sickle cell disease (57)
Southern California (2191)
Special edition (18)
Spinal muscular atrophy (166)
Sponsored (33)
Startups (4286)
State (2)
Stomach cancer (16)
Supply chain (67)
Tariffs (14)
The Weekly (77)
United States (22848)
Vaccines (775)
Venture capitalists (39)
Webinars (13)
Weight loss (291)
Women's health (38)
Worklife (19)
Date
Today (109)
Last 7 days (709)
Last 30 days (2827)
Last 365 days (36230)
2025 (8968)
2024 (37959)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1271)
Alabama (56)
Alaska (7)
Arizona (261)
Arkansas (14)
Asia (49982)
Australia (8811)
California (5865)
Canada (1922)
China (510)
Colorado (264)
Connecticut (281)
Delaware (138)
Europe (114551)
Florida (854)
Georgia (209)
Hawaii (1)
Idaho (64)
Illinois (587)
India (29)
Indiana (317)
Iowa (10)
Japan (147)
Kansas (108)
Kentucky (27)
Louisiana (12)
Maine (69)
Maryland (907)
Massachusetts (4548)
Michigan (235)
Minnesota (401)
Mississippi (2)
Missouri (87)
Montana (31)
Nebraska (26)
Nevada (58)
New Hampshire (69)
New Jersey (1678)
New Mexico (31)
New York (1673)
North Carolina (1076)
North Dakota (8)
Northern California (2520)
Ohio (207)
Oklahoma (15)
Oregon (45)
Pennsylvania (1302)
Puerto Rico (10)
Rhode Island (30)
South America (1650)
South Carolina (19)
South Dakota (1)
Southern California (2191)
Tennessee (98)
Texas (882)
Utah (175)
Virginia (152)
Washington D.C. (65)
Washington State (562)
West Virginia (3)
Wisconsin (62)
843,249 Results for "anpac bio medical science co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
WORK Medical Technology Group LTD Announces Strategic Partnership with Shanghai Chartwell Medical Device Co., Ltd.
March 3, 2025
·
5 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Press Releases
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025
March 31, 2025
·
12 min read
Pharm Country
AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering
AnPac Bio-Medical Science Co., Ltd. announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs.
April 6, 2023
·
6 min read
Pharm Country
AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering
AnPac Bio-Medical Science Co., Ltd. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares, pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.
March 31, 2023
·
8 min read
Pharm Country
AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.
AnPac Bio-Medical Science Co., Ltd. announced that on March 31, 2023, the Company entered into an asset purchase agreement with Easy Hundred Inc., a U.S.-based e-commerce company in the foodservice industry, through which the Company will acquire certain fixed assets of Easy Hundred and Easy Hundred’s intellectual property relating to ez100, 2Supply and 100WAY.
April 3, 2023
·
6 min read
Deals
AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider
AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC) announced the closing of the acquisition of GISN (HK) LIMITED (“GISN”), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises.
February 15, 2023
·
6 min read
Pharm Country
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements
AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC) announced that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors.
January 25, 2023
·
4 min read
Deals
AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023
AnPac Bio-Medical Science Co., Ltd. announced that on March 22, 2023, the Company has been notified by the Nasdaq Hearings Panel (“Panel”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s request for continued listing on The Capital Market has been granted.
March 23, 2023
·
6 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
1 of 84,325
Next
